• Arvinas posted Q2 net income of $169.4 million, swinging from a year-earlier loss; diluted EPS was $2.58.
• Revenue more than doubled to $249.7 million, driven by VEPPANU-related collaboration and licensing items, including Pfizer and Rigel agreements.
• R&D expense fell 23.32% to $52.6 million; GAAP G&A expense slipped 5.14% to $24 million.
• Cash, cash equivalents and marketable securities totaled $567.9 million at June 30, down $117.5 million from Dec. 31.
• VEPPANU won FDA approval then was out-licensed to Rigel; management flagged Phase 1 data updates for ARV-393, ARV-102, ARV-027 within 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9802970) on August 04, 2026, and is solely responsible for the information contained therein.